Concurrently, the anti-inflammatory property of CEP enables its use in the treatment of cerebral ischemia/reperfusion injury, wherein CEP inhibits NLRP3 signaling, and caspase-1, thereby suppressing the overproduction of IL-1β and IL-18, thus attenuating cerebral ischemia/reperfusion injury [44]. The gene discussed is NLRP3; the disease is brain ischemia.